This phase 2a randomised trial shows that a single intranodular injection of 40 mg adalimumab in 0.4 ml in patients with Dupuytren's disease is safe and leads to down regulation of the myofibroblast phenotype as evidenced by reduced expression of α-SMA and type I procollagen proteins. The gene discussed is COL1A2; the disease is Dupuytren Contracture.